Stephen Miller, director of clinical psychology training at UGA, and his research colleagues focused on antibodies that the body creates in response to two proteins that are associated with Alzheimer’s disease. (Photo by Peter Frey)
Early diagnosis
Study suggests blood test
for Alzheimer’s may be possible
Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer’s disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.
Researchers from UGA, the Charlie Norwood VA Medical Center in Augusta and the Medical College of Georgia compared antibody levels in blood samples from 118 older adults with the participant’s level of dementia. The team, whose results appear in the current edition of Journal of Gerontology: Medical Sciences, found that the concentration of two specific proteins that are involved in the immune response increases as the severity of dementia increases.
“We found a strong and consistent relationship between two particular antibodies and the level of impairment,” said study co-author L. Stephen Miller, professor and director of clinical psychology training in UGA’s Franklin College of Arts and Sciences. “The finding brings us closer to our ultimate goal of developing a blood test that can diagnose Alzheimer’s disease or potentially identify if someone is at higher risk for the disease.”
Miller’s co-authors include Jennifer S. Wilson, a former undergraduate student in the UGA Honors program who is now pursing graduate studies at Emory University; Shyamala Mruthinti, research pharmacologist at the VA Medical Center and adjunct professor at MCG; and Jerry Buccafusco, director of the MCG Alzheimer’s Research Center. The team focused on antibodies that the body creates in response to two proteins that are associated with Alzheimer’s disease. One protein, known as amyloid-beta, forms the plaques that are evident in the brains of people with Alzheimer’s upon autopsy. The other protein, known as RAGE, is involved in the normal aging process but is expressed at higher levels in the brains of people with Alzheimer’s.
In a previous study that compared a group of people with Alzheimer’s disease to a healthy control group, Mruthinti and her colleagues found that anti-amyloid beta and anti-RAGE antibodies are significantly higher in the group with Alzheimer’s. The team’s latest study expands on that finding to reveal a direct relationship between severity of Alzheimer’s disease and levels of the two antibodies in the blood.
“Alzheimer’s is an inflammatory disease of the brain, and these two antibodies give us a way to measure that inflammation,” Mruthinti said. “Using them as an early diagnostic marker may allow us to start drug treatment early, when it’s most effective, to increase the patient’s quality of life.”
While optimistic about their findings, the researchers caution that it could still be years before a diagnostic test based on their work is clinically available. The study found that the relationship between the two antibodies and Alzheimer’s severity persists even after controlling for patient age and total antibody levels. To further test the strength of the relationship, the researchers are now working with a sample that controls for other factors that have the potential to influence levels of the two antibodies, such as diabetes and heart disease. Buccafusco and his colleagues also are working to decrease the cost and time involved in the test.
“We’re in the process of trying to reduce the test to a one-day procedure, whereas right now it takes three to four days,” Buccafusco said. “But even now, our test is orders of magnitude cheaper than having people come in every few months to get a functional MRI or PET scan to try to discern brain plaques.”
The team is targeting the two proteins themselves as a possible treatment for Alzheimer’s disease. Mruthinti explains that, individually, amyloid-beta and RAGE proteins don’t provoke immune responses. The trouble begins when the two bind and the immune system attacks, resulting in constant state of inflammation that damages the brain. The researchers recently developed a way to measure levels of amyloid beta-RAGE complex, and preliminary data using transgenic mice that express Alzheimer’s symptoms suggest that an antigen they created to boost the body’s natural immune response to the complex can reduce the formation of the brain plaques.
“The amyloid beta-RAGE complex cuts off the connections between neurons,” Mruthinti said, “but our hope is that we can protect those connections by preventing those plaques from forming.”
The research was funded by a Merit Review Award from the Veterans Administration to principal investigator Mruthinti and by the Medical College of Georgia Alzheimer’s Research Center.
Columns
is produced by the UGA News Service, a unit of UGA Public Affairs. 286 Oconee St., Ste. 200N, Athens, GA 30602-1999 Juliett
Dinkins (jdinkins@uga.edu):
editor (706) 542-8017, Janet Beckley (jbeckley@uga.edu):
art director (706) 542-8170, Peter Frey (pfrey@uga.edu):
photo editor (706) 542-8086, Matthew
Weeks (mweeks@uga.edu): senior reporter (706) 542-8024, Sara
Freeland (freeland@uga.edu): reporter (706) 542-8077
Questions or comments should be directed to columns@uga.edu
------------------------------------------------------------------------ Copyright 2008-2009 University of Georgia. All rights reserved
The University of Georgia • Athens, GA 30602 | UGA Directory Assistance
706/542-3000
UGA Home | UGA Today | Public
Affairs Directory
